A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.
A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.
Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters.
Johnson & Johnson's dividend currently yields more than 3%. The healthcare giant has increased its payout every year for more than half a century.
Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?